Javascript must be enabled to continue!
Diagnosis and treatment options of neuroendocrine tumours
View through CrossRef
Neuroendocrine neoplasms belong to the group of rare tumours. Their clinical importance may be highlighted by their high prevalence despite low incidence. Since survival rate is similar to other progressive neoplastic diseases in metastatic cases, early recognition and appropriate therapy of these neoplasms are equally important. Classification of neuroendocrine tumours is based on their pathologic characteristics according to the 2010 WHO recommendation. Non-functioning tumours cause local symptoms due to their mass effect, while functioning tumours produce well-defined endocrine syndromes. Among laboratory tests, serum chromogranin-A is considered the most important biomarker of both non-functioning and functioning neuroendocrine tumours. Localization of these tumours includes the use of conventional diagnostic imaging, endoscopic examinations, and functional imaging studies. With respect to treatment, elimination of the primary tumour remains one of the most important issues. In advanced cases of the disease metastasectomy, interventional radiologic methods, medical treatment and endoradiotherapy can be used. The aim of this review is to summarize briefly the symptoms, diagnostic methods and treatment options of neuroendocrine tumours. Orv. Hetil., 2013, 154, 1549–1555.
Title: Diagnosis and treatment options of neuroendocrine tumours
Description:
Neuroendocrine neoplasms belong to the group of rare tumours.
Their clinical importance may be highlighted by their high prevalence despite low incidence.
Since survival rate is similar to other progressive neoplastic diseases in metastatic cases, early recognition and appropriate therapy of these neoplasms are equally important.
Classification of neuroendocrine tumours is based on their pathologic characteristics according to the 2010 WHO recommendation.
Non-functioning tumours cause local symptoms due to their mass effect, while functioning tumours produce well-defined endocrine syndromes.
Among laboratory tests, serum chromogranin-A is considered the most important biomarker of both non-functioning and functioning neuroendocrine tumours.
Localization of these tumours includes the use of conventional diagnostic imaging, endoscopic examinations, and functional imaging studies.
With respect to treatment, elimination of the primary tumour remains one of the most important issues.
In advanced cases of the disease metastasectomy, interventional radiologic methods, medical treatment and endoradiotherapy can be used.
The aim of this review is to summarize briefly the symptoms, diagnostic methods and treatment options of neuroendocrine tumours.
Orv.
Hetil.
, 2013, 154, 1549–1555.
Related Results
Pulmonary carcinoid tumours
Pulmonary carcinoid tumours
Key pointsPulmonary carcinoid tumours account for 2% of all lung tumours, with an increase in incidence due to more accurate diagnostic techniques.Carcinoid tumours are relatively ...
Rare genital system tumours, neuroendocrine neoplasms: case series and literature review
Rare genital system tumours, neuroendocrine neoplasms: case series and literature review
Neuroendocrine neoplasms (NENs) of the female genital tract are rare tumours. They behave more aggressively than other gynaecological cancers. Clinical presentation and treatment a...
A Clinicopathological Study of Parotid Gland Tumours
A Clinicopathological Study of Parotid Gland Tumours
Abstract
Background:
The parotid gland is the largest salivary gland. Pleomorphic adenoma (PA) is the most common tumour found in the parotid gla...
Abstract 1801: FOXA1, a novel regulator of neuroendocrine differentiation
Abstract 1801: FOXA1, a novel regulator of neuroendocrine differentiation
Abstract
Neuroendocrine prostate cancer (NEPC) is a subtype of prostate cancer that is highly aggressive and exhibits a neuroendocrine phenotype, being distinct from...
Neuroendocrine Biomarkers
Neuroendocrine Biomarkers
Neuroendocrine cells are unique because they are found in almost every organ in the body. These cells often resemble other cell types, making it challenging to differentiate them b...
Localization of immunoreactive HIF‐1α and HIF‐2α in neuroendocrine cells of both benign and malignant prostate glands
Localization of immunoreactive HIF‐1α and HIF‐2α in neuroendocrine cells of both benign and malignant prostate glands
AbstractBACKGROUNDHypoxia induces increased tumor growth by promoting angiogenic and glycolytic pathways. Tumors expressing hypoxia‐inducible factor‐1α (HIF‐1α), an important trans...
Exploring Large Language Models Integration in the Histopathologic Diagnosis of Skin Diseases: A Comparative Study
Exploring Large Language Models Integration in the Histopathologic Diagnosis of Skin Diseases: A Comparative Study
Abstract
Introduction
The exact manner in which large language models (LLMs) will be integrated into pathology is not yet fully comprehended. This study examines the accuracy, bene...
[68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors
[68Ga]-DOTATOC PET/CT Volumetric Parameters Reflect Metastatic Potential in Pancreatic Neuroendocrine Tumors
Background: [68Ga]-DOTATOC PET/CT is a valuable technique for identifying neuroendocrine tumors overexpressing somatostatin receptors; however, its diagnostic and prognostic utilit...

